Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer

Inclusion Criteria * Metastatic colorectal cancer * Tumor classified WT KRAS * At least 18 yrs of age * ECOG PS 0,1 or 2 * Evidence of adequate organ function * Measurable disease per RECIST criteria * Have at least two of the following criteria: * Age \> 65 years * ECOG PS 1 or 2 * Serum Albumin \< or equal to 3.5g/dL * Prior RT to abdomen or pelvis * Stopped first-line combination systemic chemotherapy \< 6 weeks duration Exclusion Criteria * Tumors classified as KRAS mutation * Prior therapy with cetuximab, panitumumab or other agent that targets EGFR * Prior exposure to any biologic * Known sensitivity to cetuximab or 5-FU (or marked intolerance to 5-FU) * Known DPD deficiency * Uncontrolled angina or a myocardial infarction within the previous 12 months * Concurrent severe uncontrolled medical illness * Known uncontrolled CNS metastases * Bowel disease associated with chronic diarrhea * Major surgery within 28 days